Browse
Submit Data
Databases
API
Help

Dataset Information

22 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

ABSTRACT: The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.

DISEASE(S): Stomach Cancer,Kidney Neoplasms,Lung Cancer,Colorectal Cancer,Bladder Cancer,Liver Cancer,Pancreatic Cancer,Breast Cancer,Ovarian Cancer,Uterine Neoplasms,Renal Pelvis Cancer,Esophageal Cancer,Uterine Cancer,Prostate Cancer,Kidney Cancer,Stomach Neoplasms,Pelvic Neoplasms

PROVIDER: 2283452 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Blood and Stool Sample Collection in Subjects Participating in Colorectal Cancer Screening: Act Bold

Project description:The primary objective of this study is to collect de-identified, clinically-characterized stool and whole blood specimens for use in developing and evaluating the performance of new biomarker assays for detection of colorectal cancer (CRC).

| 2295726 | ecrin-mdr-crc

Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast

| 2293208 | ecrin-mdr-crc

Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers

Project description:The primary objective of this study is to obtain de-identified, clinically characterized, stool and plasma specimens for use in assessing new markers for the detection of neoplasms of the digestive tract.

| 2194576 | ecrin-mdr-crc

Stool Collection Sub-Study of Exact Sciences Protocol 2018-01

Project description:The primary objective of this sub-study is to obtain de-identified, clinically characterized, stool specimens from subjects with untreated solid tumors for research use in the development and validation of a stool-based test for colorectal cancer.

| 2345779 | ecrin-mdr-crc

A Multicenter Cancer Biospecimen Collection Study

Project description:This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.

| 2348584 | ecrin-mdr-crc

Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Project description:The objective of this study is to confirm the sensitivity of a stool DNA test for detection of colorectal cancer and pre-cancer. Another objective is to provide anonymous, clinically characterized specimens for a bio-repository for future colorectal cancer-related test development.

| 2099543 | ecrin-mdr-crc

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing – Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND2)

Project description:Interventions: Group 1: one blood draw in cancer patients (breast cancer, lung cancer, colorectal cancer, prostate cancer, bladder cancer, uterine cancer, kidney/renal pelvis cancer, pancreatic cancer, liver cancer, stomach cancer, ovarian cancer, esophageal cancer, head and neck squamous cell cancer, thyroid cancer, small intestine cancer, cervical cancer, anal cancer, vulva cancer, testicular cancer) after study consent Group 2: one blood draw in healthy subjects Primary outcome(s): The primary objective of this study is to obtain clinically characterized, whole blood specimens from cancer and healthy subjects to develop and refine assays for cancer in the blood. Study Design: Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: other

| 93757 | ecrin-mdr-crc

Identification of biomarkers for Miltefosine resistance in Leishmania donovani

Project description:To identify biomarkers specific for Miltefosin resistant parasites, we used DNA microarray to identify differentially expressed genes in resistant parasite in comparision to sensitive and further validated with real time PCR assay and immunoblotting assay Clinically proven miltefosine reistant as well as respondant parasite strains isolated from splenic aspirates and grown in M199 media. For microarray resistant and sensitive samples run in duplicate while for real time PCR, 25 resistant and 33 sensitive strains used. For immunoblotting, confirmed genes were cloned and recombinant protein blotted against miltefosine failure and treated patients sera.

2014-01-31 | E-GEOD-53738 | biostudies-arrayexpress

Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortality

Project description:We profiled DNA from primary tumour RP tissue specimens from 15 patients (and adjacent normal tissue specimens from 4 patients) in a discovery cohort using whole-genome bisulphite sequencing (WGBS). We identified a set of differentially methylated regions in the primary tumour samples between patients who died ≤ 10 yrs post-RP and those still alive > 10 yrs post RP (median follow-up time: 19.5 years).

2022-10-03 | GSE158927 | GEO

Potential Prognostic Biomarkers for Bone Metastasis from Hepatocellular Carcinoma

Project description:RNA was extracted from 48 pairs of intratumoral and peritumoral formalin-fixed, paraffin-embedded (FFPE) tissue from hepatocellular carcinoma (HCC) patients with and without bone metastases (BM). The Human Cancer Panel DASL Assay containing 502 cancer-related genes was used to identify novel BM-associated genes. A cDNA-mediated annealing, selection, extension, and ligation assay was performed with an array of 502 known cancer-related genes to identify differentially expressed genes in 96 RNA samples. Total RNA was purified from the tissue specimens using the High Pure RNA Paraffin Kit according to the manufacturer’s protocol. DASL experiments were performed to identify genes that were differentially expressed between the BM and NBM groups of matched intratumoral and peritumoral tissues by using A cDNA-mediated annealing, selection, extension, and ligation assay.

2011-10-27 | E-GEOD-27635 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data